Aberrant promoter methylation of the SFRP1 gene may contribute to colorectal carcinogenesis: a meta-analysis

Tumor Biology

Volumn 35, Issue 9, 2014, Pages 9201-9210

  Chen, Yan Zhi ^a   Liu, Dan ^a   Zhao, Yu Xia ^a   Wang, He Tong ^a   Gao, Ya ^a   Chen, Ying ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal carcinogenesis; Meta analysis; Promoter methylation; SFRP1

Indexed keywords

SECRETED FRIZZLED RELATED PROTEIN 1; MEMBRANE PROTEIN; SFRP1 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ARTICLE; ASIAN; CANCER PATIENT; CANCER TISSUE; CAUCASIAN; COHORT ANALYSIS; COLON CARCINOGENESIS; COLORECTAL CANCER; DNA METHYLATION; ETHNICITY; GENE FREQUENCY; HUMAN; PROMOTER REGION; SYSTEMATIC REVIEW; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOGENESIS; COLORECTAL TUMOR; ETHNOLOGY; GENETICS; META ANALYSIS; RISK;

ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOGENESIS; COLORECTAL NEOPLASMS; DNA METHYLATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; ODDS RATIO; PROMOTER REGIONS, GENETIC;

EID: 84919847901     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2180-x     Document Type: Article

References (32)

1. Meyer JE, Narang T, Schnoll-Sussman FH, Pochapin MB, Christos PJ, Sherr DL. Increasing incidence of rectal cancer in patients aged younger than 40 years: an analysis of the surveillance, epidemiology, and end results database. Cancer. 2010;116(18):4354–9.
2. Kanojia D, Garg M, Gupta S, Gupta A, Suri A. Sperm-associated antigen 9 is a novel biomarker for colorectal cancer and is involved in tumor growth and tumorigenicity. Am J Pathol. 2011;178(3):1009–20.
3. Shen H, Yuan Y, Hu HG, Zhong X, Ye XX, Li MD, et al. Clinical significance of K-ras and BRAFmutations in Chinese colorectal cancer patients. World J Gastroenterol. 2011;17(6):809–16.
4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer. 2010;127(12):2893–917.
5. Rawson JB, Manno M, Mrkonjic M, Daftary D, Dicks E, Buchanan DD, et al. Promoter methylation of Wnt antagonists DKK1 and SFRP1 is associated with opposing tumor subtypes in two large populations of colorectal cancer patients. Carcinogenesis. 2011;32(5):741–7.
6. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22(4):191–7.
7. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst. 2010;102(6):365–7.
8. Dahm CC, Keogh RH, Spencer EA, Greenwood DC, Key TJ, Fentiman IS, et al. Dietary fiber and colorectal cancer risk: a nested case-control study using food diaries. J Natl Cancer Inst. 2010;102(9):614–26.
9. Amatu A, Sartore-Bianchi A, Moutinho C, Belotti A, Bencardino K, Chirico G, et al. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. Clin Cancer Res. 2013;19(8):2265–72.
10. Huang D, Yu B, Deng Y, Sheng W, Peng Z, Qin W, et al. SFRP4 was overexpressed in colorectal carcinoma. J Cancer Res Clin Oncol. 2010;136(3):395–401.
11. Salehi R, Mohammadi M, Emami MH, Salehi AR. Methylation pattern of SFRP1 promoter in stool sample is a potential marker for early detection of colorectal cancer. Adv Biomed Res. 2012;1:87.
12. Bovolenta P, Esteve P, Ruiz JM, Cisneros E, Lopez-Rios J. Beyond Wnt inhibition: new functions of secreted frizzled-related proteins in development and disease. J Cell Sci. 2008;121(Pt 6):737–46.
13. Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, et al. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene. 2006;25(24):3479–88.
14. Fre S, Pallavi SK, Huyghe M, Lae M, Janssen KP, Robine S, et al. Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine. Proc Natl Acad Sci U S A. 2009;106(15):6309–14.
15. Dhir M, Montgomery EA, Glockner SC, Schuebel KE, Hooker CM, Herman JG, et al. Epigenetic regulation of WNT signaling pathway genes in inflammatory bowel disease (IBD) associated neoplasia. J Gastrointest Surg. 2008;12(10):1745–53.
16. Chung MT, Lai HC, Sytwu HK, Yan MD, Shih YL, Chang CC, et al. SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway. Gynecol Oncol. 2009;112(3):646–53.
17. Garcia-Hoyos M, Cantalapiedra D, Arroyo C, Esteve P, Rodriguez J, Riveiro R, et al. Evaluation of SFRP1 as a candidate for human retinal dystrophies. Mol Vis. 2004;10:426–31.
18. Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: past, present and future. Patholog Res Int. 2011;2011:902674.
19. Qi J, Zhu YQ, Luo J, Tao WH. The role of secreted Wnt-antagonist genes hypermethylation in early detection of colorectal tumor. Chin Med J. 2007;28:1954–7.
20. Wang W, Zhang B, Yan XJ, Wang J, Zhang N, Zhao CH. Effect of Wnt antagonist SFRP1 in the pathogenesy of colorectal cancer. Journal of China Medical University. 2012;41(5):440–3.
21. Shao SX, Liao XJ, Zhang YX, Qiu JM, Zhang XF, Yang GG. Multi-gene methylation detection increases positive methylation rate in colorectal cancer. Chin J Gastrointestinal Surg. 2012;15(6):629–32.
22. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.
23. Zintzaras E, Ioannidis JP. Hegesma: Genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005;21(18):3672–3.
24. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28(2):123–37.
25. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.
26. Konishi K, Shen L, Wang S, Meltzer SJ, Harpaz N, Issa JP. Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias. Gastroenterology. 2007;132(4):1254–60.
27. Guo YL, Wang FL, Guo W, Kuang G, Yang ZB, Dong ZM. Hypermethylation of SFRP1 and DKK3 promoters in gastric cardia adenocarcinoma. Chin J Clin Exper Pathol. 2010;26(2):154–7.
28. Dong LJ, Gu XY, Jiang Z. Detection and significance of serum SFRP1 promoter methylation status in patients with colorectal cancer. Jiangsu Med J. 2010;36(18):2153–5.
29. Cheng CW, Yeh JC, Fan TP, Smith SK, Charnock-Jones DS. Wnt5a-mediated non-canonical Wnt signalling regulates human endothelial cell proliferation and migration. Biochem Biophys Res Commun. 2008;365(2):285–90.
30. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8(5):387–98.
31. Ying Y, Tao Q. Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. Epigenetics. 2009;4(5):307–12.
32. Jiang GX, Liu W, Cui YF, Zhong XY, Tai S, Wang ZD, et al. Reconstitution of secreted frizzled-related protein 1 suppresses tumor growth and lung metastasis in an orthotopic model of hepatocellular carcinoma. Dig Dis Sci. 2010;55(10):2838–43.